Professional paper

Extensive clinical experience with clopidogrel in the treatment of acute coronary syndrome

Darja Milovanovič Jarh ; Krka, d. d., Novo mesto, Slovenia
Breda Barbič-Žagar orcid.org/0000-0002-1173-7361 ; Krka, d. d., Novo mesto, Slovenia
Mateja Grošelj ; Krka, d. d., Novo mesto, Slovenia

Abstract

Acute coronary syndrome (ACS) is a major problem for healthcare systems, as it is the cause of a large number of hospitalisations every year. Moreover, as ACS may be a life-threatening condition, timely decisions on pharmacological management as well as coronary revascularisation strategies are needed. Clopidogrel has a strong evidence base supporting its use as an effective and well tolerated antiplatelet agent for the secondary prevention of ischemic events in patients with various cardiovascular conditions, including those with ACS. An evidence base demonstrating the efficacy and safety of antiplatelet therapy has also been established for Zyllt® (Krka's clopidogrel) in many post-authorisation safety and efficacy studies. The studies yielded important results and an extensive data base, which is not available for any other generic clopidogrel. The high efficacy and good safety as well as the reasonable price of Krka’s clopidogrel could undoubtedly contribute to a better compliance with the treatment in more patients with ACS.

Keywords

acute coronary syndrome; secondary prevention; clopidogrel

Hrčak ID:

74636

URI

https://hrcak.srce.hr/74636

Publication date:

15.11.2011.

Article data in other languages: croatian

Visits: 1.811 *